Related Videos
Video
Omar Nadeem, MD discusses results of the Phase II d-PRISM study
Daratumumab in high-rish MGUS and low-risk smoldering myeloma
Video
Omar Nadeem, MD, Discusses Immuno-PRISM Trial
At #ASH23, Omar Nadeem, MD, Dana-Farber, presented findings from the phase 2 clinical trial, Immuno-PRISM. Results suggest early use of #immunotherapy may have even greater benefit for people with high-risk smoldering myeloma.
